Drug Interactions Associated with HAART: Focus on Treatments for Addiction and Recreational Drugs

AIDS Reader

Volumn 13, Issue 9, 2003, Pages 433-434+437

  Faragon, John J ^a   Piliero, Peter J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Addiction therapy; Antiretroviral therapy; Drug interactions; HIV AIDS; Recreational drug use

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ABACAVIR; AMPHETAMINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CANNABIS; DELAVIRDINE; DIAMORPHINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE; STREET DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; COMORBIDITY; DRUG DEPENDENCE; HALF LIFE TIME; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; REVIEW; SIDE EFFECT; SUBSTANCE ABUSE; SURVIVAL; DRUG INTERACTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; METHADONE; STREET DRUGS;

EID: 0242380247     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Centers for Disease Control and Prevention. Drug-Associated HIV Transmission Continues in the United States. Available at: http://www.cdc.gov/hiv/pubs/facts/idu.htm. Accessed August 17, 2003.
2. Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med. 1994;331:1422-1427.
3. Astemborski J, Vlahov D, Warren D, et al. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health. 1994;84:382-387.
4. de Souza CT, Diaz T, Sutmoller F, et al. The association of socioeconomic status and use of crack/cocaine with unprotected anal sex in a cohort of men who have sex with men in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2002;29:95-100.
5. Stein MD, Hanna L, Natarajan R, et al. Alcohol patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abuse Treat. 2000;18:359-363.
6. Rees V, Saitz R, Horton NJ, et al. Association of alcohol consumption with HIV sex- and drug-risk behaviors among drug users. J Subst Abuse Treat. 2001;21:129-134.
7. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:137-139.
8. Hansten PD. Drug interactions. In: Koda-Kimble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs. Vancouver: Applied Therapeutics Inc; 1995:1-3.
9. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-996.
10. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45:355-359.
11. Hoetelmans RMV, Piscitelli SC, Hill AM. A Guide to Protease Inhibitor Boosting. Basel, Switzerland: Hoffman-LaRoche; 2001:1-15, 42.
12. Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2002.
13. Hivid [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2001.
14. Retrovir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
15. Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2002.
16. Epivir [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
17. Ziagen [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002.
18. Emtriva [package insert]. Foster City, Calff: Gilead Sciences: 2003.
19. Viread [package insert]. Foster City, Calif: Gilead Sciences; 2001.
20. Viramune [package insert]. Columbus, Ohio: Roxane Laboratories; 2002.
21. Rescriptor [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2001.
22. Sustiva [package insert]. Princeton, NJ: Bristol Meyers Squibb; 2002.
23. Agenerase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 1999.
24. Kaletra [package insert]. North Chicago: Abbott Laboratories; 2000.
25. Crixivan [package insert]. Readington Township, NJ: Merck and Company; 2000.
26. Norvir [package insert]. North Chicago: Abbott Laboratories; 2000.
27. Invirase [package insert]. Basel, Switzerland: Hoffmann-LaRoche; 1998.
28. Fortovase [package insert]. Basel, Switzerland: Hoffmann-LaRoche; 1997.
29. Viracept [package insert]. Lo Jolla, Calif: Agouron Pharmaceuticals; 2000.
30. Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2003.
31. New York State Department of Health AIDS Institute. Clinical Guidelines. HIV Drug-Drug Interactions. Available at: http://www.hivguidelines.org. Accessed July 10, 2003.
32. Fuzeon [package insert]. Nutley, NJ: Roche Laboratories and Trimeris Inc; 2003.
33. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9:365-373.
34. Schwartz EL, Brechbuhl AB, Kahl P, et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr. 1992;5:619-626.
35. McCance-Katz EF, Rainey PM, Jatlow P, et al. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:435-443.
36. Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addict. 2002;11:66-74.
37. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr. 2000;24:241-248.
38. Friedland G, Rainey P, Jatlow P, et al. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) versus chewable tablet formulation (EC) in patients (pts) on chronic methadone therapy. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuPeB4548.
39. Sellers E, Lam R, McDowell J, et al. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following coadministration: CNAA1012. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29,1999; San Francisco. Abstract 663.
40. Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 869.
41. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy. 1999;19:471-472.
42. Otero MJ, Fuertes A, Sanchez R, et al. Nevirapine induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS. 1999;13:1004-1005.
43. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
44. Pinzanni V, Faucherre V, Peyiere H, et al. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother. 2000;34:405-407.
45. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001;33:1595-1597.
46. Clarke SM, Mulcahy FM, Tjia J. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2000;51:213-217.
47. Booker B, Smith P, Forrest A. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine and N-delavirdine (NDLV). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract A-490.
48. Hsu A, Granneman GR, Carothers L, et al. Ritonavir decreases methadone exposure in healthy volunteers. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5,1998; Chicago. Abstract 324.
49. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000;20:93-94.
50. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27:153-160.
51. Shelton, MJ, Cloen D, Berenson C, et al. Pharmacokinetics (PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects on unbound methadone and alphal acid-glycoprotein (AAG). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract A-492.
52. Cantilena L, McCrea J, Blazes D, et al. Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Ther. 1999;65:135. Abstract PI-74.
53. Smith PF, Booker BM, Difrancesco R, et al. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract A-491.
54. Hsyu PH, Lillibridge JH, Maroldo L, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 4, 2000; San Francisco. Abstract 87.
55. Maroldo L, Manocchio S, Artenstein A, et al. Lack of effect on nelfinavir mesylate on maintenance methadone dose requirement. In: Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePeB4120.
56. Brown LS, Chu M, Aug C, Dabo S. The use of nelfinavir and two nucleosides concomitantly with methadone is effective and well-tolerated in hepC co-infected patients. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract 206.
57. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methadone levels with nelfinavir mesylate. Am J Psychiatry. 2000;157:481.
58. Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit. 2001;23:553-555.
59. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir/ritonavir. Clin Infect Dis. 2002;34:1143-1145.
60. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000;67:429-436.
61. ORLAAM [package insert]. Columbus, Ohio: Roxane Pharmaceuticals; 2002.
62. McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addiction. 2001;10:296-307.
63. Johnson PE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opiate dependence. JAMA. 1992;267:2750-2755.
64. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475-486.
65. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
66. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998;26:818-821.
67. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60:1953-1964.
68. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylation by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26:257-260.
69. Revia [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2001.
70. Antabuse [package insert]. East Hanover, NJ: Odyssey Pharmaceuticals; 2001.
71. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses. 2002;18:757-770.
72. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
73. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a larger cohort of drug users. J Hepatol. 1998;28:945-950.
74. Raffi F, Benhamou D, Sereni, et al. Pharmacokinetics of, and tolerability to, a single, oral 600 mg dose of abacavir in HIV-positive subjects with or without liver disease. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto. Poster 1630.
75. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
76. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
77. McDowell JA, Chittick GE, Pilati Stevens C, et al. Pharmacokinetic interaction of abacavir and ethanol in human immunodefidency virus-infected patients. Antimicrob Agents Chemother. 2000;44:1686-1690.
78. Staszewski S, Katlama C, Hareer T, et al. A dose ranging study to evaluate the safety and efficacy of three doses of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment naive subjects. In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva. Abstract 12212.
79. Prentiss D, Balmas D, Tsuang G, et al. Prevalence of medicinal marijuana use in HIV infected individuals in a public health care setting. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires. Abstract 380.
80. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002;16:543-550.
81. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of "ecstasy" -related designer drugs. Biochem Pharmacol. 2000;59:1563-1571.
82. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751-1752.
83. Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999;159:2221-2224.
84. Pellinen P, Honkakoski P, Stenback, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P4503A inhibitors. Eur J Pharmacol. 1994;270:35-43.
85. Kashuba A, Lim ML. Interactions between heroin and antiretrovirals? Medscape HIV/AIDS. Available at: http://www.medscape.com. Accessed July 11, 2003.
86. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther. 1999;66:33-39.
87. Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther. 2000;67:335-341.
88. Greenblatt DJ, Von Moltke LL, Harmatz, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr. 2000;24:129-136.
89. Lin LY, Kumagai Y, Hiratsuka A, et al. Cytochrome P4502D isoenzymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Dispos. 1995;23:610-614.
90. Tong TG, Benowitz NL, Kreek MJ. Methadone-disulfiram interaction during methadone maintenance. J Clin Pharmacol. 1980;20:506-513.